Invitation to presentation of half-year results 2016 of Molecular Partners AG Donnerstag, 25. August 2016 - 14:58

Molecular Partners AG: Half-year results 2016 of Molecular Partners AG

Thursday, September 01,2016, 2:00pm (CET) –

Conference call & audio webcast for media, analysts, and investors

Dear Sir/Madam

Molecular Partners AG cordially invites you to participate in the conference call or audio webcast of the company’s Half-year results 2016 which will take place as follows:

Date:	Thursday, September 01, 2016
Time:	2:00pm CET (1:00pm GMT, 8:00am EST)

The Half-year 2016 Report and additional information is available from 7:00am (CET) on Thursday, September 01, 2016.

Best regards,
Investor Relations Molecular Partners AG

Dial-ins for the conference call:
Switzerland / Europe	+41 (0) 58 310 5000
UK	+44 (0) 203 059 5862
USA	+1 (1) 631 570 5613

Please dial-in approximately 10 minutes before the start of the presentation in order to register. Participants will have the opportunity to ask questions after the presentation.

To follow the audio webcast of the presentation:
The audio webcast will be accessible, both live and as a replay, on www.molecularpartners.com, along with the accompanying presentation slides.
Please note that there will be no facility to ask questions via the webcast.
You will need to log in and register prior to the event.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to:www.molecularpartners.com.